Fraser, Hannah
Borquez, Annick
Stone, Jack
Abramovitz, Daniela
Brouwer, Kimberly C.
Goodman-Meza, David
Hickman, Matthew
Patterson, Thomas L.
Silverman, Jay
Smith, Laramie
Strathdee, Steffanie A.
Martin, Natasha K.
Vickerman, Peter
Funding for this research was provided by:
National Institute on Drug Abuse (R01 DA03773, R37 DA019829, DP2DA049295, R01 DA033679)
National Institute of Allergy and Infectious Diseases (R01AI147490)
University of San Diego Center for AIDS Research, an NIH funded program (P30 AI036214)
NIHR Health Protection Research Unit in Evaluation of interventions and Behavioural Science
Article History
Accepted: 20 June 2021
First Online: 3 July 2021
Declarations
:
: HF has received an honorarium from MSD. JS reports non-financial support from Gilead. MH has received unrestricted honoraria from Gilead and MSD in last 2 years. NM has received unrestricted research grants from Gilead and Merck. PV has received honoraria from Gilead and Abbvie unrelated to this research, and unrestricted research funding from Gilead unrelated to this work. All other authors have no disclosures.
: Not applicable because modelling analysis.
: Not applicable.
: Not applicable.